About
Akero Therapeutics develops investigational therapies for metabolic diseases, focusing primarily on efruxifermin (EFX), a treatment for metabolic dysfunction-associated steatohepatitis (MASH).
Explore Akero's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.